Position of the academy of nutrition and dietetics: dietary fatty acids for healthy adults.

It is the position of the Academy of Nutrition and Dietetics (the Academy) that dietary fat for the healthy adult population should provide 20% to 35% of energy, with an increased consumption of n-3 polyunsaturated fatty acids and limited intake of saturated and trans fats. The Academy recommends a food-based approach through a diet that includes regular consumption of fatty fish, nuts and seeds, lean meats and poultry, low-fat dairy products, vegetables, fruits, whole grains, and legumes. These recommendations are made within the context of rapidly evolving science delineating the influence of dietary fat and specific fatty acids on human health. In addition to fat as a valuable and calorically dense macronutrient with a central role in supplying essential nutrition and supporting healthy body weight, evidence on individual fatty acids and fatty acid groups is emerging as a key factor in nutrition and health. Small variations in the structure of fatty acids within broader categories of fatty acids, such as polyunsaturated and saturated, appear to elicit different physiological functions. The Academy recognizes that scientific knowledge about the effects of dietary fats on human health is young and takes a prudent approach in recommending an increase in fatty acids that benefit health and a reduction in fatty acids shown to increase risk of disease. Registered dietitian nutritionists are uniquely positioned to translate fat and fatty acid research into practical and effective dietary recommendations.

Feasibility studies. The use of NMR spectrometry as a possible substitute of or complement to several analytical tests in pharmacopoeia monographs.

NMR spectrometry has many analytical applications; for instance, the identification of known substances; the structure elucidation of unknown ones; the quantification of APIs, impurities, solvent and water; kinetic studies, stereochemistry determinations, and the analyses of complex mixtures as in metabonomics. NMR spectrometry has the potential to substitute or complement existing analyses that are performed on APIs. In this work, 4 different NMR analyses were done on 2 APIs: fluvastatin sodium and benzalkonium chloride with good results.

Mobile mating disruption of light-brown apple moths using pheromone-treated sterile Mediterranean fruit flies.

BACKGROUND: Public opposition to aerial application of sex pheromone for mating disruption of light-brown apple moth (LBAM), Epiphyas postvittana (Walk.), in California stopped its further use in the ca $74 million eradication programme in 2008, underscoring the need for other eradication tactics. It is demonstrated that pheromone-treated sterile Mediterranean fruit flies (medflies), Ceratitis capitata Wied., can disrupt communication in male moths. RESULTS: Medflies topically dosed with moth pheromone (E)-11-tetradecenyl acetate showed a no observed effect level (NOEL) of ~10 µg fly(-1) , with increasing toxicity from 30 to 100 µg fly(-1) . Greater potency and longevity of attraction and lower mortality were achieved using microencapsulated pheromone. Releases of 1000 pheromone-treated medflies ha(-1) prevented male moth catch to synthetic lures in treated 4 ha plots for 1 day in suburban Perth, Australia. Releases of ca 3000 pheromone-treated medflies ha(-1) disrupted catch to single female moths in delta traps, and to synthetic pheromone lures. Percentage disruption on the first four nights was 95, 91, 82 and 85%. CONCLUSIONS: Disruption of moth catch using pheromone-treated medflies is a novel development that, with future improvement, might provide a socially acceptable approach for application of the insect mating disruption technique to control invasive insects in urban environments. Adequacy of payload and other issues require resolution.

Influence of dietary levels of fat, fiber, and copper sulfate and fat rancidity on cecal activity in the growing turkey.

Two experiments were conducted with 6- to 10-wk-old turkeys. In Experiment 1, 6-wk-old turkeys were fed diets varying in level of fat (4.4 to 10%) or fiber (2.5 to 9.0%). The diets also contained extra copper as copper sulfate at either 0.1 or 0.2% of the diet. At 8 wk of age, 15 replicate birds were housed in individual cages and all excreta was collected. Excreta was separated as being "regular" or "cecal" in origin based on appearance. At 10 wk of age, 10 birds per treatment were killed and cecal contents removed under anaerobic conditions. Cecal contents were assayed for various nutrients and viscosity was measured. In a second comparable study, turkeys were fed animal-vegetable fat or regular or rancid canola oil (60.25 vs 120.24 ng/g malonaldehyde, respectively). In Experiment 1, feeding copper sulfate had the most noticeable effect on various cecal parameters. There was an increase (P < 0.01) in dry matter cecal droppings produced and the cecal contents were of increased viscosity (P < 0.05). Copper had no effect on pH or microbial colony count of the cecal contents. Feeding copper resulted in a significant increase in the high molecular weight (> 300,000) fraction of cecal contents and this fraction was of higher viscosity. Feeding copper sulfate resulted in a dramatic increase in copper content of cecal contents (280 to 11,848 ppm), although the copper content of regular excreta was also increased (17 to 1,008 ppm). The various levels of fiber and fat generally had no effect on cecal parameters. Feeding rancid canola oil did result in increased viscosity of cecal contents, compared to the situation seen with fresh canola oil. Fat rancidity per se, however, failed to influence other parameters such as total mass of cecal material produced and composition of cecal material. Feeding copper sulfate or rancid fat will increase the viscosity of cecal material, which may contribute to litter management problems.

Effects of forage level and canola seed supplementation on site and extent of digestion of organic matter, carbohydrates, and energy by steers.

The objective of this study was to determine the effects of fat supplementation from canola seed (CS) on ruminal fermentation and postruminal digestion of OM, carbohydrates, and energy of diets containing different levels of forage. Six ruminally and duodenally cannulated beef steers (354 kg +/- 18) were given ad libitum access to six isonitrogenous diets that were offered twice daily in a 6 x 6 Latin square design. Treatments were arranged as a 2 x 3 factorial with two forage levels (70 vs 30% of dietary DM as corn silage) and three forms of CS supplementation including no CS or CS added at 10% of dietary DM as whole CS treated with alkaline hydrogen peroxide or untreated crushed CS. Fat from CS provided 5% of dietary DM. The remaining dietary ingredients were corn, canola meal, molasses, and urea. No interactions (P > .05) between dietary forage level and CS supplementation were observed for ruminal characteristics or digestion of OM, carbohydrates, and energy in the rumen, postruminally, or in the total tract. Fat supplementation from CS did not affect (P > .05) DMI. With few exceptions, fat supplementation did not affect (P > .05) ruminal, postruminal, or total tract digestibilities of OM, structural and nonstructural carbohydrates, and GE. Ruminal disappearance of GE was decreased (P < .05) when diets were supplemented with fat from whole treated CS, and total tract digestibilities of OM and GE were decreased (P < .05) when diets were supplemented with fat from CS in either form. Ruminal pH, concentrations of NH3 N and total VFA, and molar proportions of acetate, propionate, and butyrate were not affected (P > .05) by fat supplementation. Results suggest that fat supplementation from CS (at 5% of dietary DM) as whole treated or untreated crushed had no negative effects on ruminal fermentation of OM, carbohydrates, or energy when steers were given ad libitum access to diets containing high or low forage.

Composition of ruminal bacteria harvested from steers as influenced by dietary forage level and fat supplementation.

The objective of this study was to examine the effects of dietary forage level and fat supplementation on the chemical composition of mixed ruminal bacteria (MRB). Six ruminally cannulated beef steers (354 kg +/- 18) were given ad libitum access to six diets (13.2% CP; DM basis) that were offered twice daily in a 6 x 6 Latin square design. Treatments were arranged as a 2 x 3 factorial with two forage levels (70 vs 30% of dietary DM as corn silage) and three forms of fat supplementation including no canola seed or canola seed added at 10% of dietary DM as whole treated with alkaline hydrogen peroxide or untreated crushed. Canola seed contributed 5% added fat to the total diet. The remaining dietary ingredients were corn, canola meal, molasses, and urea. No interactions (P > .05) between dietary forage level and canola seed supplementation were observed. Concentrations of OM, N, and all amino acids were higher (P < .05) in MRB from steers fed low forage than in MRB from steers fed high forage. Concentrations of purines and GE and the N:purines ratio in MRB were not affected (P > .05) by dietary forage level or canola seed supplementation. Canola seed supplementation did not affect (P > .05) concentrations of OM, N, or most of the amino acids in MRB. Concentrations of four essential amino acids (i.e., isoleucine, leucine, lysine, and phenylalanine) in MRB were decreased (P < .05) due to canola seed supplementation. Dietary forage level did not affect (P > .05) concentrations of long-chain fatty acids in MRB.(ABSTRACT TRUNCATED AT 250 WORDS)

Efficacy and safety of fluvastatin in hypertensive patients. An analysis of a clinical trial database.

The concurrence of hypertension and hypercholesterolemia leads to the clinical need to lower lipids in hypertensive patients. Thus, it is interesting to evaluate the efficacy and safety of fluvastatin, a new 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA)-reductase inhibitor, in such a patient population. A retrospective analysis of the clinical efficacy and safety of fluvastatin was based on the data from 1815 patients who received fluvastatin at daily doses of > or = 20 mg compared with 783 patients taking placebo. The results showed that 332 (18.3%) of the fluvastatin-treated and 124 (15.8%) of the placebo-treated patients were identified as having hypertension. The percentage change from baseline of low-density lipoprotein cholesterol (LDL-C) in hypertensive patients taking fluvastatin at doses of 20 and 40 mg/day was -20% and -26%, respectively (placebo: 1.4%), and did not differ from the response in non-hypertensive patients. Increases in high-density lipoprotein cholesterol (HDL-C) as well as decreases in triglycerides with fluvastatin were not consistently different between hypertensive and non-hypertensive patients. Irrespective of the presence or absence of hypertension, confirmed (measured on two consecutive occasions) increases > three times the upper limit of normal in aspartate aminotransferase (ASAT) and alanine aminotransferase (ALAT) were observed in three (0.2%) and 12 (0.7%) patients, respectively. With placebo, ALAT was increased in two patients (0.2%). The incidence of notable increases more than 10 times the upper limit of normal in creatine kinase was similar with fluvastatin compared with placebo (0.3% in both).(ABSTRACT TRUNCATED AT 250 WORDS)

Safety and tolerability of fluvastatin with concomitant use of antihypertensive agents. An analysis of a clinical trial database.

The coexistence of hypercholesterolemia and hypertension often requires concomitant drug treatments. Thus, it is interesting to evaluate the efficacy, safety, and tolerability of the new lipid-lowering agent fluvastatin, a 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA)-reductase inhibitor, in patients receiving concomitant antihypertensive/cardiovascular drug treatments. A retrospective analysis was based on data from controlled clinical trials in which 1815 patients were treated with fluvastatin and 783 patients received placebo. The daily dose of fluvastatin was > or = 20 mg. At least one of the following drug treatments was taken by 445 of the fluvastatin-treated patients (24.5%) and 181 of those receiving placebo (23.1%): beta-adrenergic-receptor blockers (fluvastatin: n = 182; placebo: n = 84); diuretics (fluvastatin: n = 168; placebo: n = 72); calcium antagonists (fluvastatin: n = 161; placebo: n = 69); and angiotensin-converting enzyme (ACE) inhibitors (fluvastatin: n = 101; placebo: n = 30). The majority of patients received monotherapy with one of the above-mentioned antihypertensive agents (fluvastatin: 69%; placebo: 65%). The efficacy of fluvastatin in modifying low-density lipoprotein (LDL)- and high-density lipoprotein (HDL)-cholesterol and triglyceride levels was not consistently different in patients taking a given antihypertensive compared with the overall group and the patients not taking the antihypertensive agent. In patients taking fluvastatin and antihypertensives, confirmed (measured at two consecutive occasions) increases more than three times the upper limit of normal in aspartate aminotransferase (ASAT) and alanine aminotransferase (ALAT) occurred in only two patients. One case involved the concomitant use of a beta-blocker (ASAT and ALAT) and the other a diuretic (ALAT).(ABSTRACT TRUNCATED AT 250 WORDS)